Medical device company Biovo Technologies Ltd revealed on Thursday that it has commissioned its Cuffix devices in the largest newly established COVID-19 ward in one of Israel's leading hospitals, with a capacity of 170 ventilated patients.
The company added that Cuffix is the first and only economical, self-contained, disposable cuff pressure regulator and monitor in the market.
As ICUs are full and medical personnel is stretched to the limit, the single use products including Cuffix can assist with treating COVID-19 patients and reduce nurse work load. This has dramatically increased worldwide interest in Biovo's products.
Under the company's plan to increase sales and production volumes, it has signed distribution agreements in Australia and Brazil and following the recent 510K FDA clearance, the next commercialization step is in the USA and discussions are already underway.
Airiver medical receives FDA approval for central airway stenosis trial
Talphera reaches enrollment milestone in NEPHRO CRRT pivotal trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets
Oncopeptides partners with SD Pharma to expand Pepaxti access in Spain
Aptar launches bio-based nasal spray pump with Haleon's Otrivin brand
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Predictmedix AI launches mobile diabetes screening platform in India
Navamedic's medical device OraFID approved as primary package for a pharmaceutical product
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions